Herman Spolders, CEO
Herman Spolders is the director of the Board of Pluriomics BV. He is responsible for the creation, structure, obtaining financing and business Development of the company.
Throughout his career, Herman Spolders has been instrumental in forging large pharma-biotech collaborations, expanding research and development organizations, defining new product opportunities, and protecting intellectual property. In addition to direct management experience, Spolders has served on the board of Organon Teknika (Akzo Nobel) and numerous international biotech companies. He founded OncoMethylome Sciences (a early cancer diagnosis and personalized medicine company) in 2003 and expanded the company to its IPO at Euronext in 2006. From 1999-2001, he managed business development and operations of Tibotec-Virco, which matured into a leading HIV/AIDS therapeutics and diagnostics company until its acquisition by Johnson & Johnson. Prior to joining Tibotec-Virco, Mr. Spolders served as vice- president of business development at Devgen, where he planned and negotiated its first licensing deals which have since become Devgen's core activity. From 1993 to 1998, he was vice-president of business development of IGEN International, and participated in its initial public offering.
Stefan Braam, CSO
Stefan Braam forms with Herman Spolders the management team. Stefan is responsible for technology development, R&D, IP, management, Operations of Services, research grants and coordinating the various external research projects. In the management team he is actively involved in company’s strategy and business development.
Stefan is the scientific founder and Chief Scientific Officer of Pluriomics. He is currently employed by the LUMC with the vision to start Pluriomics. He has over 7 years of pluripotent stem cell experience from laboratories in The Netherlands (Prof. C.L. Mummery, Utrecht/Leiden), UK (Dr. C. Denning, Nottingham) and Australia (Profs. A. Elefanty and E. Stanley, Monash, Melbourne). His work on pluripotent stem cell technology resulted in several publications in leading scientific journals (e.g Cell Stem Cell, Nature Methods, Nature Protocols, Stem Cells, Trends in pharmacological sciences, Trends in molecular medicine). Stefan also completed a Master class in BioBusiness at Nyenrode University, he won the NGI Venture Challenge in 2009 with the Pluriomics venture plan. Finally he had a major contribution in the pre-seed funding of Pluriomics through grants from NGI and STW and contract research with Janssen pharmaceutica. Mr. Braam is a Dutch national.
Meet us at the SPS in rotterdam
Pluriomics will present three posters describing our latest advances cell production and cardiac safety pharmacology assays
Preclinical Safety and Efficacy Testing meeting
Pluriomics CSO to Present at Informa Life Science Preclinical Safety and Efficacy Testing, Berlin, Germany
Safety Pharmacology Society annual meeting
Pluriomics will present a poster describing our latest advances in cardiac safety pharmacology